Evidence map›Paper›PMID 37522109›Full record

ArticleClinical neuropsychiatry2023

Partial Response to Antidepressant Treatment: The Role of Nutraceutical Compounds.

Nicolaja Girone, Beatrice Benatti, Laura Molteni, Niccolò Cassina, Luca Giacovelli, Chiara Arici, Bernardo Dell'Osso

Open access · greenAbstract read
In one paragraph

Article in Clinical neuropsychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Nutraceuticals in Psychiatric Disorders: A Systematic Review.International journal of molecular sciences · 2024
    Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article Highlights.Clinical neuropsychiatry · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Nicolaja GironeLuigi Sacco University Hospital, Psychiatry 2 Unit, University of Milan, Milan, Italy.
Beatrice BenattiLuigi Sacco University Hospital, Psychiatry 2 Unit, University of Milan, Milan, Italy.
Laura MolteniLuigi Sacco University Hospital, Psychiatry 2 Unit, University of Milan, Milan, Italy.
Niccolò CassinaLuigi Sacco University Hospital, Psychiatry 2 Unit, University of Milan, Milan, Italy.
Luca GiacovelliLuigi Sacco University Hospital, Psychiatry 2 Unit, University of Milan, Milan, Italy.
Chiara AriciDepartment of Mental Health and Addiction, ASST Brianza, Vimercate, Italy.
Bernardo Dell'OssoLuigi Sacco University Hospital, Psychiatry 2 Unit, University of Milan, Milan, Italy.
University of Milan · ITLuigi Sacco Hospital · ITAzienda Ospedaliera di Desio e Vimercate · ITStanford University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Depression represents one of the most severe psychiatric disorders, characterized by low mood episodes, as well as loss of interest. Major Depressive Episodes (MDE) treatment relies primarily on monoaminergic prescriptions. However, although the presence of many antidepressant medications, their efficacy is still partial. A promising intervention to improve antidepressant treatment may be the use of adjunctive nutraceuticals. Aim of the present study was to assess the efficacy of a N-Acetyl-cysteine, S-Adenosyl-L-Methionine and Folic acid's combination for the treatment of depressive symptoms in a sample of MDE patients. Method: Fifty outpatients with a MDE diagnosis in the context of different psychiatric disorders such as Major Depression, Bipolar Disorder, Anxiety disorders, and Personality disorders were recruited. The sample was divided into different groups based on the nutraceutical administration: a) concurrently with an AD (starter group); b) add-on to an already prescribed treatment; c) single treatment. Results: A significant reduction of CGI-Severity and Improvement scores from baseline to the end of treatment was found. Moreover, the starter group showed a significantly greater CGI-Improvement score compared to the other groups. Ninety-four percent of patients did not show any side effects. Conclusions: The present study showed promising results for the use of nutraceuticals in the add-on treatment of MDE. Those compounds may be considered a versatile, tolerable, and effective add-on treatment for the reduction of depressive symptoms impact and for improving the functioning of patients affected by MDE.

Indexed as

adjunctivemajor depressive episodenutraceutical

Identifiers

PMID37522109
PMCPMC10375276
OpenAlexW4385406337

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.